Alimohammad Moradi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alimohammad Moradi has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Amir Kasraianfard
Liver Transplantation Research Center Tehran University of Medical Sciences Tehran Iran
2 shared publications - Ali Jafarian
Liver Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran
1 shared publication - Amirhossein Heidari
Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran
1 shared publication - Faeze Salahshour
Department of Radiology, Advanced Diagnostic and Interventional Radiology Research Center (ADIR), Tehran University of Medical Sciences, Tehran, Iran
1 shared publication - Hossein Malekee
Department of General Surgery, School of Medicine, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran
1 shared publication - Mahsa Kargar
Department of Pathology, Cancer Institute Tehran University of Medical Sciences Tehran Iran
1 shared publication
Latest Publications
- Open Access
- 28 September 2026
- Published by Springer Nature in Journal of Medical Case Reports
Mixed-type intraductal papillary mucinous neoplasm with oncocytic and signet-ring features: a case report
- 28 September 2026
- Published by Springer Nature in Journal of Medical Case Reports
Open AccessMixed-type intraductal papillary mucinous neoplasm with oncocytic and signet-ring features: a case report
- Open Access
- 10 September 2025
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 8 (5) , e70107
Peri‐Liver Transplant Hyperglycemia: Mechanisms, Associated Factors, Consequences, and Management – A Systematic Review
Introduction: Liver transplantation is associated with various metabolic disorders. Peri‐transplant hyperglycemia is among the most frequent metabolic disorders among liver transplant recipients. Hyperglycemia following liver transplantation can increase the risk of post‐transplant complications, potentially impacting both graft and recipient outcomes. Several studies have compared intensive with standard blood glucose control strategies in liver transplant recipients. However, a comprehensive protocol for managing peri‐transplant hyperglycemia remains elusive. This review aimed to synthesise existing literature on the mechanisms, associated factors, and consequences of hyperglycemia after liver transplantation, and to provide recommendations for managing hyperglycemia in this patient population. Method: PubMed, Scopus, and UpToDate databases and American Diabetes Association guidelines were searched without time limitations until February 2025. Results: Peri‐liver transplant hyperglycemia can be attributed to several factors, including post‐reperfusion hepatocyte injury, insulin resistance stemming from underlying liver disease, surgical stress, and the use of immunosuppressive drugs. Various factors associated with peri‐transplant hyperglycemia can be categorised into pre‐transplant recipient factors, intraoperative factors, and donor‐related factors. Research has shown that inadequate glycemic control during the peri‐transplant period may have detrimental effects on post‐transplant outcomes, including an increased incidence of infections, graft rejection, acute kidney injury, prolonged hospital stays, and higher overall mortality. Conclusion: The suggestions presented in this article, which consider the recipient's medical history and clinical conditions, can serve as a framework for healthcare providers to manage peri‐liver transplant hyperglycemia effectively.
- 10 September 2025
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 8 (5) , e70107
Open AccessPeri‐Liver Transplant Hyperglycemia: Mechanisms, Associated Factors, Consequences, and Management – A Systematic Review
Introduction: Liver transplantation is associated with various metabolic disorders. Peri‐transplant hyperglycemia is among the most frequent metabolic disorders among liver transplant recipients. Hyperglycemia following liver transplantation can increase the risk of post‐transplant complications, potentially impacting both graft and recipient outcomes. Several studies have compared intensive with standard blood glucose control strategies in liver transplant recipients. However, a comprehensive protocol for managing peri‐transplant hyperglycemia remains elusive. This review aimed to synthesise existing literature on the mechanisms, associated factors, and consequences of hyperglycemia after liver transplantation, and to provide recommendations for managing hyperglycemia in this patient population. Method: PubMed, Scopus, and UpToDate databases and American Diabetes Association guidelines were searched without time limitations until February 2025. Results: Peri‐liver transplant hyperglycemia can be attributed to several factors, including post‐reperfusion hepatocyte injury, insulin resistance stemming from underlying liver disease, surgical stress, and the use of immunosuppressive drugs. Various factors associated with peri‐transplant hyperglycemia can be categorised into pre‐transplant recipient factors, intraoperative factors, and donor‐related factors. Research has shown that inadequate glycemic control during the peri‐transplant period may have detrimental effects on post‐transplant outcomes, including an increased incidence of infections, graft rejection, acute kidney injury, prolonged hospital stays, and higher overall mortality. Conclusion: The suggestions presented in this article, which consider the recipient's medical history and clinical conditions, can serve as a framework for healthcare providers to manage peri‐liver transplant hyperglycemia effectively.
- Open Access
- 15 September 2024
- Published by Wiley in Clinical Case Reports
- Vol. 12 (9) , e9427
Successful management of a ruptured cystic artery pseudoaneurysm with embolization and cholecystectomy: A case report
Key Clinical Message: Cystic artery pseudoaneurysm is a rare phenomenon associated with cholecystitis. We describe the successful management of angioembolisation and cholecystectomy. Cystic artery pseudoaneurysm (CAP) is a rare but clinically significant condition with various etiological factors. Cholecystitis is a prominent cause, often leading to inflammation‐induced arterial wall erosion and pseudoaneurysm formation. CAP can present with a range of symptoms, including hemobilia, upper GI bleeding, and jaundice. Despite its rarity, CAP warrants attention in emergency care due to its potential for life‐threatening arterial bleeding. Timely diagnosis is crucial, with imaging techniques playing a key role. Depending on the clinical context, management options include endovascular embolization and surgical intervention. Due to the limited cases, standard protocols remain elusive. A 64‐year‐old woman presented with abdominal pain, anorexia, and weight loss, prompting an evaluation for possible gallbladder cancer. She experienced sudden abdominal pain and upper gastrointestinal bleeding (hematemesis). Laboratory findings revealed leukocytosis, anemia, and abnormal liver function tests. Imaging showed gallbladder wall thickening, luminal contraction, and a pseudoaneurysm in the cystic artery. The patient underwent angioembolization followed by cholecystectomy, confirming acute cholecystitis and CAP with thrombosis. This case underscores the importance of early recognition and appropriate management in CAP, particularly when accompanied by acute cholecystitis.
- 15 September 2024
- Published by Wiley in Clinical Case Reports
- Vol. 12 (9) , e9427
Open AccessSuccessful management of a ruptured cystic artery pseudoaneurysm with embolization and cholecystectomy: A case report
Key Clinical Message: Cystic artery pseudoaneurysm is a rare phenomenon associated with cholecystitis. We describe the successful management of angioembolisation and cholecystectomy. Cystic artery pseudoaneurysm (CAP) is a rare but clinically significant condition with various etiological factors. Cholecystitis is a prominent cause, often leading to inflammation‐induced arterial wall erosion and pseudoaneurysm formation. CAP can present with a range of symptoms, including hemobilia, upper GI bleeding, and jaundice. Despite its rarity, CAP warrants attention in emergency care due to its potential for life‐threatening arterial bleeding. Timely diagnosis is crucial, with imaging techniques playing a key role. Depending on the clinical context, management options include endovascular embolization and surgical intervention. Due to the limited cases, standard protocols remain elusive. A 64‐year‐old woman presented with abdominal pain, anorexia, and weight loss, prompting an evaluation for possible gallbladder cancer. She experienced sudden abdominal pain and upper gastrointestinal bleeding (hematemesis). Laboratory findings revealed leukocytosis, anemia, and abnormal liver function tests. Imaging showed gallbladder wall thickening, luminal contraction, and a pseudoaneurysm in the cystic artery. The patient underwent angioembolization followed by cholecystectomy, confirming acute cholecystitis and CAP with thrombosis. This case underscores the importance of early recognition and appropriate management in CAP, particularly when accompanied by acute cholecystitis.